SNIPERs

IAP-dependent Protein Eraser, Specific and Nongenetic inhibitor of apoptosis protein [IAP]-dependent Protein Erasers

Specific and Non-genetic inhibitor of apoptosis protein [IAP]-dependent Protein Erasers (SNIPER), a class of small-molecule degraders, is designed to induce IAP-mediated ubiquitylation and proteasomal degradation of target proteins.

SNIPERs recruit IAP family of RING-type E3 ligases-cIAP1, cIAP2, and XIAP. The SNIPER chemical structure consists of selective IAP antagonist (i.e., Bestatin, MV1, and LCL161), PEG linker and peptide- or small-molecule-based protein of interest (POI)-specific component. Unlike the chimeric molecules that recruit von Hippel-Lindau and cereblon ubiquitin ligases, SNIPERs induce simultaneous degradation of IAPs such as cIAP1 and XIAP along with the target proteins.

SNIPERs Inhibitors

Biotin-BS

Cat. No.: HY-111879

Biotin-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and biotin, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BzNH-BS

Cat. No.: HY-111878

BzNH-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and benzoyl-amide, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC AR Degrader-4

Cat. No.: HY-111848

PROTAC AR Degrader-4 comprises a **IAP** ligand binding group, a linker and an **Androgen Receptor** (**AR**) binding group. PROTAC AR Degrader-4 is an **AR** degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (**SNIPER**s).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC AR Degrader-4 TFA

Cat. No.: HY-111848A

PROTAC AR Degrader-4 comprises a **IAP** ligand binding group, a linker and an **Androgen Receptor** (**AR**) binding group. PROTAC AR Degrader-4 is an **AR** degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (**SNIPER**s).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

PROTAC CRABP-II Degrader-1

Cat. No.: HY-111840

PROTAC CRABP-II Degrader-1 is a potent cellular retinoic acid binding protein (**CRABP-II**) degrader based on **IAP** ligand.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC CRABP-II Degrader-2

Cat. No.: HY-111841

PROTAC CRABP-II Degrader-2 is a potent cellular retinoic acid binding protein (**CRABP-II**) degrader based on **IAP** ligand.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC CRABP-II Degrader-3

Cat. No.: HY-111842

PROTAC CRABP-II Degrader-3 is a potent cellular retinoic acid binding protein (**CRABP-II**) degrader based on **IAP** ligand.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC ERα Degrader-2

Cat. No.: HY-111846

PROTAC ERα Degrader-2 comprises a **IAP** ligand binding group, a linker and an **estrogen receptor α** (**ERα**) binding group. PROTAC ERα Degrader-2 is an **ERα** degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

PROTAC RAR Degrader-1

Cat. No.: HY-111844

PROTAC RAR Degrader-1 comprises a **IAP** ligand binding group, a linker and a **RAR** ligand binding group. PROTAC RAR Degrader-1 is an **RAR** degrader. Maximal RAR degradation at 30 μM concentration in HT1080 cells.



Purity: 95.02%
Clinical Data: No Development Reported
Size: 1 mg

SNIPER(ABL)-013

Cat. No.: HY-111860

SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 20 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-015

Cat. No.: HY-111854

SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 5 μM .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-019

Cat. No.: HY-111873

SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 0.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-020

Cat. No.: HY-111872

SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

SNIPER(ABL)-024

Cat. No.: HY-111861

SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 5μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-033

Cat. No.: HY-111871

SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 0.3 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-039

Cat. No.: HY-111874

SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 10 nM. IC_{50}s are 0.54 nM, 10 nM, 12 nM, and 50 nM for **ABL**, cIAP1, cIAP2, XIAP, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-044

Cat. No.: HY-111862

SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-047

Cat. No.: HY-111863

SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-049

Cat. No.: HY-111851

SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 100 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-050

Cat. No.: HY-111858

SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ABL)-058

Cat. No.: HY-111859

SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (**IAP** ligand) with a linker, induces the reduction of **BCR-ABL** protein with a DC_{50} of 10 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(BRD)-1

Cat. No.: HY-111875

SNIPER(BRD)-1, consists of an **IAP** antagonist LCL-161 derivative and a **BET** inhibitor, (+)-JQ-1, connected by a linker. SNIPER(BRD)-1 induces the degradation of **BRD4** via the ubiquitin-proteasome pathway.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 1 mg

SNIPER(ER)-110

Cat. No.: HY-122825

SNIPER(ER)-110 consists of a **IAP** ligand and an estrogen ligand, connected by a linker. SNIPER(ER)-51 induces **estrogen receptor** (**ER**) protein degradation with DC_{50}s of <3 nM and 7.7 nM after 4 h and 48 h, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(ER)-87

Cat. No.: HY-129619

SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (**IAP**) ligand LCL161 derivative that is conjugated to the estrogen receptor α (**ERα**) ligand 4-hydroxytamoxifen by a PEG linker, and efficiently degrades the **ERα** protein (IC_{50}=0.097 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(TACC3)-1

Cat. No.: HY-111876

SNIPER(TACC3)-1 targets the **TACC3** protein for degradation via the ubiquitin-proteasome pathway based on **IAP** ligand. SNIPER(TACC3)-1 induces cancer cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(TACC3)-11

Cat. No.: HY-145895

SNIPER(TACC3)-11 is a potent **FGFR3-TACC3** degrader. SNIPER(TACC3)-11 reduces FGFR3-TACC3 protein levels and suppressed the growth of FGFR3-TACC3 positive cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNIPER(TACC3)-2

Cat. No.: HY-111877

SNIPER(TACC3)-2 targets the TACC3 protein for degradation via the ubiquitin-proteasome pathway based on **IAP** ligand. SNIPER(TACC3)-2 induces cancer cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg